3,973 Shares in Gilead Sciences, Inc. $GILD Bought by Leo Wealth LLC

Posted by Brian Himes on Oct 28th, 2026

Gilead Sciences logo Leo Wealth LLC acquired a new stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 3,973 shares of the biopharmaceutical company’s stock, valued at approximately $592,000.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. BlackRock Inc. acquired a new stake in Gilead Sciences in the second quarter worth $15,393,785,000. State Street Corp lifted its stake in Gilead Sciences by 2.3% in the second quarter. State Street Corp now owns 61,216,552 shares of the biopharmaceutical company’s stock valued at $7,734,099,000 after buying an additional 1,357,967 shares during the last quarter. Amundi boosted its holdings in shares of Gilead Sciences by 10.7% during the first quarter. Amundi now owns 10,539,111 shares of the biopharmaceutical company’s stock valued at $1,468,836,000 after acquiring an additional 1,018,976 shares during the period. Legal & General Group Plc acquired a new position in shares of Gilead Sciences during the second quarter valued at $1,316,606,000. Finally, Deutsche Bank AG acquired a new position in shares of Gilead Sciences during the second quarter valued at $918,387,000. Institutional investors and hedge funds own 83.67% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on GILD shares. Jefferies Financial Group restated a “buy” rating and set a $185.00 price target on shares of Gilead Sciences in a research report on Friday. Morgan Stanley cut their price objective on shares of Gilead Sciences from $165.00 to $163.00 and set an “overweight” rating on the stock in a research report on Wednesday, October 7th. Barclays reduced their target price on shares of Gilead Sciences from $155.00 to $145.00 and set an “equal weight” rating for the company in a research note on Wednesday, July 29th. Weiss Ratings raised Gilead Sciences from a “hold (c-)” rating to a “hold (c)” rating in a research note on Monday, September 14th. Finally, Royal Bank Of Canada boosted their price target on Gilead Sciences from $123.00 to $126.00 and gave the stock a “sector perform” rating in a research report on Thursday, October 8th. Twenty-three equities research analysts have rated the stock with a Buy rating and six have given a Hold rating to the company’s stock. Based on data from MarketBeat, Gilead Sciences has an average rating of “Moderate Buy” and an average target price of $159.81.

Check Out Our Latest Research Report on GILD

Insider Activity at Gilead Sciences

In related news, CEO Daniel O’Day sold 15,000 shares of the stock in a transaction dated Thursday, October 1st. The stock was sold at an average price of $147.90, for a total value of $2,218,500.00. Following the completion of the sale, the chief executive officer directly owned 566,683 shares of the company’s stock, valued at approximately $83,812,415.70. This represents a 2.58% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Jeffrey Bluestone sold 5,000 shares of the firm’s stock in a transaction dated Thursday, August 20th. The stock was sold at an average price of $145.02, for a total value of $725,100.00. Following the sale, the director owned 10,066 shares of the company’s stock, valued at $1,459,771.32. The trade was a 33.19% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 111,000 shares of company stock worth $15,877,860. Insiders own 0.30% of the company’s stock.

Gilead Sciences Trading Up 0.2%

NASDAQ:GILD opened at $159.08 on Wednesday. Gilead Sciences, Inc. has a 1-year low of $114.02 and a 1-year high of $160.51. The stock has a fifty day simple moving average of $149.65 and a 200 day simple moving average of $139.13.

Gilead Sciences (NASDAQ:GILD – Get Free Report) last issued its quarterly earnings results on Monday, August 3rd. The biopharmaceutical company reported ($6.75) EPS for the quarter, beating the consensus estimate of ($7.25) by $0.50. The firm had revenue of $7.80 billion during the quarter, compared to analysts’ expectations of $7.40 billion. During the same quarter last year, the company posted $2.01 EPS. The firm’s revenue was up 10.6% compared to the same quarter last year. Sell-side analysts anticipate that Gilead Sciences, Inc. will post -0.48 EPS for the current year.

Key Headlines Impacting Gilead Sciences

Here are the key news stories impacting Gilead Sciences this week:

Positive Sentiment: Analyst commentary suggests Gilead could be substantially undervalued if new oncology trial data validate the company’s pipeline and create a larger long-term growth opportunity. Gilead Stock Could Be 50% Undervalued on New Oncology Trial News
Positive Sentiment: Gilead reached an agreement with Canada’s pan-Canadian Pharmaceutical Alliance for public reimbursement of LYVDELZI (seladelpar), improving potential access and commercial prospects for the primary biliary cholangitis treatment. Gilead Reaches Canadian Reimbursement Agreement for LYVDELZI
Positive Sentiment: An analyst raised the company’s fiscal 2026 EPS forecast, providing a modest fundamental tailwind ahead of earnings. FY2026 EPS Forecast for Gilead Sciences Raised
Positive Sentiment: Gilead’s latest deal highlights pharmaceutical-industry interest in oral peptide therapies, potentially strengthening the company’s longer-term growth strategy and business-development profile. Gilead Deal Shows Big Pharma Appetite for Oral Peptides
Neutral Sentiment: Gilead is preparing to report third-quarter results. Strong HIV sales, Yeztugo momentum and oncology developments could support the shares, but analysts also flag competitive pressure. Gilead Q3 Earnings Preview
Neutral Sentiment: Wall Street’s pre-earnings estimates focus on revenue, earnings and operating metrics for the quarter ended September 2026; the reports offer expectations but do not represent released results. Gilead Q3 Wall Street Estimates
Negative Sentiment: Exchange-traded funds were reported as net sellers of Gilead shares on October 23, indicating some short-term institutional selling pressure. ETFs Are Net Sellers of Gilead

Gilead Sciences Profile

(Free Report)

Gilead Sciences, Inc is a biopharmaceutical company that discovers, develops and commercializes medicines for serious and life-threatening diseases. The company is best known for its HIV treatments, including Biktarvy, Descovy, Genvoya and Truvada, as well as therapies for chronic hepatitis B and hepatitis C. Its portfolio also includes Veklury (remdesivir), an antiviral treatment for COVID-19.

Gilead has expanded into oncology and cell therapy through products such as Trodelvy and the CAR T-cell therapies Yescarta and Tecartus, which are developed and marketed through its Kite subsidiary.